YOUR SHARE TIP FOR 2002

THIS SHOULD BECOME A MULTI BAGGER.Given the way ISTA is surging in the us and the fact that THERATASE supply the key ingredients this has massive upside potential.A pe of about 9,the ISTA deal has to worth the current value alone,then the stake in pharmAAware,a sector switch and re-rating plus rumours on another bb of a deal with a european pharma.Tipped all over the place,the f.d reckons their worth £4 a share.When the squeeze on this begins(and i think it already has)they could do an ASD and shoot to a tenner-a forward pe of about 120 not daft considering the stuff in the pipeline.Need i go on????






THERATASE PLC


ANNOUNCES POSITIVE TRADING UPDATE


Theratase plc (LSE: THE), one of the world's leading manufacturers and
suppliers of enzymes and biochemicals to the diagnostic industry, today
announces that revenue in the year to 30 September 2001 is expected to come in
just ahead of its broker's forecast, whilst Group profit before tax for the
full year is likely to be in line with its broker's forecast.



The Board of Theratase anticipates that Group turnover for the year will show
significant growth over the year ended 30 September 2000 (2000: £5,691m).
This will be due, in the main, to improved sales in North America and the UK
of glucose oxidase, one of Theratase's best selling enzymes. Glucose oxidase
is used in the production of tests for home diabetes monitoring - a market
which continues to grow by well in excess of 10% per annum.



Overall the Group's Business has not been adversely affected either by the
appalling events of September 11th or the current economic downturn.
Traditionally, the healthcare markets that Theratase plc's subsidiary, Biozyme
Laboratories Ltd, supplies with enzymes have not been affected by recession.



Other positive factors that have benefited Theratase over the last few months
include the signing of the PharmAAware contract, announced in October, to
develop therapeutics and diagnostics in the field of sepsis and septic shock.
This was a key landmark for Theratase plc underscoring its commitment to the
therapeutic enzyme market. It is the Board's intention to update the Market
on the progress of this exciting project in January 2002. Additionally the
relationship with ISTA Pharmaceuticals continues to strengthen as both
organisations move forward to ensure full GMP (Good Manufacturing Practice)
compliance for the biopharmaceutical, VitraseTM.



Finally, the London Stock Exchange recently announced the launch of a new
index for healthcare companies - the FTSE techMARK mediscience index. This
index comprises 48 listed healthcare companies and includes Theratase plc.
From 1 January 2002 the Group will also be re-classified from healthcare to
the new biotechnology sub-sector of the FTSE pharmaceutical sector - we
believe that this will more accurately reflect the Group's current and future
business.